NF2 and benign neoplasm: It has been demonstrated that in the NF2-SWN population there is a 6% 20-year risk of malignancy following radiation therapy for benign tumours in comparison to < 1% risk for tumours that have not undergone irradiation, so radiotherapy is not recommended as a first line treatment for people with a germline pathogenic NF2 variant [10].